A case of alopecic primary cutaneous adenoid cystic carcinoma successfully managed with the aid of prostate-specific membrane antigen-positron emission tomography imaging
DOI:
https://doi.org/10.18203/issn.2455-4529.IntJResDermatol20261934Keywords:
Primary cutaneous adenoid cystic carcinoma, Prostate specific membrane antigen, PSMA-PET imagingAbstract
Primary cutaneous adenoid cystic carcinoma (PCACC) is a rare adnexal malignancy, most commonly affecting the scalp, and typically characterised by slow growth, marked local invasiveness and a high rate of local recurrence. Distant metastasis however remains uncommon. We report a case of a 58-year-old woman with a 6-year history of a progressively enlarging tender alopecic scalp lesion. Histopathology demonstrated a dermal basaloid neoplasm with tubular, nested and cribriform architecture and prominent perineural invasion, consistent with adenoid cystic carcinoma. Immunohistochemical studies highlighted a ductal cell component positive for cytokeratin 7 and CD117, and a myoepithelial cell component positive for smooth muscle actin and p40. Initial staging with 18F-fluorodeoxyglucose-positron emission tomography/ computed tomography (18F-FDG PET/CT) showed no significant metabolic activity or metastatic disease. Given emerging evidence of prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma, 68Ga-PSMA PET/CT was performed and demonstrated moderate uptake confined to the primary scalp lesion without regional or distant disease. The patient underwent staged wide local excision with clear histological margins and split-thickness skin graft reconstruction. Six-month follow-up 68Ga-PSMA PET/CT showed no evidence of residual or recurrent disease. To the authors’ knowledge this is first documented case of PSMA-avid PCACC and suggests that 68Ga-PSMA PET/CT may have a role in staging and surveillance of this rare tumour. Further studies are required to support these findings.
References
Ko YH, Lee MA, Hong YS, Lee KS, Jung CK, Kim YS, et al. Prognostic factors affecting the clinical outcome of adenoid cystic carcinoma of the head and neck. Jpn J Clin Oncol. 2007;37(11):805-11. DOI: https://doi.org/10.1093/jjco/hym119
Boggio R. Adenoid cystic carcinoma of scalp. Arch Dermatol. 1975;111(6):793-4. DOI: https://doi.org/10.1001/archderm.1975.01630180121024
Prieto Granada CN, Zhang L, Antonescu CR, Dry SM, Westra WH, Longacre TA. Primary cutaneous adenoid cystic carcinoma with MYB aberrations: report of three cases and comprehensive review of the literature. J Cutan Pathol. 2017;44(2):201 9. DOI: https://doi.org/10.1111/cup.12856
Tan BF, Tan WC, Wang FQ, Lechner M, Schartinger VH, Tan DS, et al. PSMA PET imaging and therapy in adenoid cystic carcinoma and other salivary gland cancers: a systematic review. Cancers (Basel). 2022;14(15):3585. DOI: https://doi.org/10.3390/cancers14153585
Klein Nulent T, Valstar MH, Smit LA, Smeele LE, Zuithoff NPA, de Keizer B, et al. al. Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck. BMC Cancer. 2020;20(1):519. DOI: https://doi.org/10.1186/s12885-020-06847-9
Wang JH, Kiess AP. PSMA-targeted therapy for non-prostate cancers. Front Oncol. 2023;13:1220586. DOI: https://doi.org/10.3389/fonc.2023.1220586
Ramakrishnan R, Chaudhry IH, Ramdial P, Lazar AJ, McMenamin ME, Kazakov D, et al. Primary cutaneous adenoid cystic carcinoma: a clinicopathologic and immuno histochemical study of 27 cases. Am J Surg Pathol. 2013;37:1603-11. DOI: https://doi.org/10.1097/PAS.0b013e318299fcac
Dores GM, Huycke MM, Devesa SS, Garcia CA. Primary cutaneous adenoid cystic carcinoma in the United States: incidence, survival, and associated cancers, 1976 to 2005. J Am Acad Dermatol. 2010;63:71-8. DOI: https://doi.org/10.1016/j.jaad.2009.07.027
van Boxtel W, Lütje S, van Engen-van Grunsven ICH, Verhaegh GW, Schalken JA, et al. 68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. Theranostics. 2020;12;10(5):2273-83. DOI: https://doi.org/10.7150/thno.38501
Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 1999;59:3192-8.
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81-5.
Wernicke AG, Varma S, Greenwood EA, et al. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS. 2014;122(6):482-9. DOI: https://doi.org/10.1111/apm.12195
Urso L, Castello A, Rocca GC, Lancia F, Panareo S, Cittanti C, et al. Role of PSMA-ligands imaging in renal cell carcinoma management: current status and future perspectives. J Cancer Res Clin Oncol. 2022;148(6):1299-311. DOI: https://doi.org/10.1007/s00432-022-03958-7
Isgoren S, Hekimsoy T, Koroglu E, Demir H. PET/CT with 68Ga-PSMA and 18F-FDG in metastatic adenoid cystic carcinoma: report of 2 cases. Clin Nucl Med. 2022;47(5):e423-4. DOI: https://doi.org/10.1097/RLU.0000000000004106